Introduction: Autoimmune hepatitis is a chronic immune-mediated liver injury, frequently associated with progression to end-stage liver disease if untreated. Patients commonly present with hepatitis, positive immune serology, elevated immunoglobulins and compatible liver histology, in the absence of an alternative aetiology.
Sources of data: Data for this review were obtained using PubMed.
Areas of agreement: Disease usually responds to steroids and azathioprine, and appears to be a manifestation of autoimmune predisposition triggered in genetically susceptible individuals exposed to likely environmental challenges. We provide an up-to-date approach to disease understanding and management along with the clinical approach to diagnosis and current treatment suggestions.
Areas of controversy: Controversies such as second line therapies and novel markers of disease activity are introduced.
Growing points: Increased understanding of the immunoregulatory mechanisms behind autoimmune hepatitis has led to opportunities for new therapies. These are developed including a discussion of timely research studies relevant to future therapies for patients.
Keywords: autoimmune liver disease; azathioprine; immune mediated liver disease; prednisolone.
© The Author 2015. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].